Neos Kicks Off Global Indie Game Publishing Business
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/
IndieTechGames
Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units.
The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units.
Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around the world. At the same time, we have also increasingly encountered indie games that, for various reasons, have not been distributed globally.
In response, Neos has launched a new label, "IndieTech Games," to bring high-quality indie games—those that developers or rights holders are unable to publish themselves—to gamers worldwide. Leveraging our experience in game planning, development, and marketing, we will discover and showcase unique and captivating indie titles, distributing them globally in collaboration with our network of regional partners.
At "IndieTech Games," we carefully select titles that, like Neos' in-house developed games, place great importance on characters, art, and storytelling. Our goal is to create a publishing label that developers feel truly glad to work with.
At launch, we plan to release the following three titles. Details on pricing and release dates will be announced separately.
Title: PIGROMANCE
Genre: Action Puzzle
Developer/Licensor: GRAVITY (Korea)
Platform: Nintendo Switch
Rating: CERO C
Territory: Worldwide
Languages: Japanese, English, Korean, French, German, Spanish, Portuguese, Simplified Chinese, Traditional Chinese
Title: SEDAP! A Culinary Adventure
Genre: Action Adventure
Developer/Licensor: kopiforge (Singapore)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Taiwan, Hong Kong, Southeast Asia
Languages: Japanese, English, Korean, Indonesian, Filipino, Malay, Simplified Chinese, Traditional Chinese
Title: Sunsethills
Genre: Puzzle Adventure
Developer: Cotton Game (China)
Licensor: Asmik Ace (Japan)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Southeast Asia
Languages: Japanese, English, Korean, Simplified Chinese, Traditional Chinese
- Official X: https://x.com/indietech_games
- Official Instagram: https://www.instagram.com/indietech_games/
- Official Facebook: https://www.facebook.com/profile.php?id=61574205204129
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320035646/en/
Contacts
Neos Corporation
URL: https://www.neoscorp.jp -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neoscorp.j
p&esheet=54226979&newsitemid=20250320035646&lan=en-US&anchor=https%3A%2F%2Fwww.n
eoscorp.jp&index=4&md5=696cf8fe9cf4103145af1e75965b2057
Inquiries:info@neoscorp.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 15:00:00 EEST | Press release
To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this manual process demands significant time and effort and can lead to inconsistent results,” said Dr. A
Pure Lithium Founder & CEO Emilie Bodoin Recognized for Trailblazing Woman of the Year at 2025 Volta Foundation Awards at 17 th Annual Fastmarkets Lithium Supply and Battery Raw Materials Conference27.6.2025 13:00:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that its Founder, Chairman & CEO, Emilie Bodoin received special recognition for Trailblazing Woman of the Year Award Sponsored by ExxonMobil at the 2025 Fastmarkets Volta Awards Ceremony, in Las Vegas, Nevada on June 24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627170164/en/ This award celebrates an exceptional female leader who has demonstrated outstanding leadership, vision, and impact within her industry. It recognizes achievements in driving innovation, fostering diversity, and inspiring others while making significant contributions to her organization. “I am truly honored to receive special recognition for this award. One of the best things about my role is the opportunity to lead by example and encourage and inspire women and girls who may not yet recognize their potential. To all of m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom